Pzena Investment Management GSK trades
Richard Pzena
Richard Pzena GlaxoSmithKline PLC ADR stake
total: 584
Trades details
- Total transactions:
- 5
- New positions:
- 1
- Added:
- 4
- Held since:
- 2025 Q2
- Held for:
- 5 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Richard Pzena holds 24,507 GlaxoSmithKline PLC ADR (GSK) shares with a market value of roughly $1.28M accounting for 0.00% of the overall portfolio. To date, the estimated cost basis is nearly $47.62 for "buy" trades. Pzena Investment Management first purchased GSK in 2025 Q2, initially acquiring 7,510 shares. Since the initial investment in GlaxoSmithKline PLC ADR (GSK), Pzena Investment Management has made 4 more transactions.
When did Richard Pzena buy GlaxoSmithKline PLC ADR (GSK)?
Richard Pzena first invested in GlaxoSmithKline PLC ADR (GSK) in 2025 Q2 at the reported quarter-end price of $38.40 per share.
What's the cost basis of Pzena Investment Management's GSK stake?
The estimated cost basis for GlaxoSmithKline PLC ADR (GSK) stake is around $47.62 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $47.62
Richard Pzena's historical trades in GlaxoSmithKline PLC ADR
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
24,507
|
$52.42
|
$1,284,635
|
+30.20% (+5,684)
|
+0%
|
|
2026 Q1
|
0.00%
|
18,823
|
$55.19
|
$1,038,836
|
+40.01% (+5,379)
|
+0%
|
|
2025 Q4
|
0.00%
|
13,444
|
$49.04
|
$659,292
|
+54.23% (+4,727)
|
+0%
|
|
2025 Q3
|
0.00%
|
8,717
|
$43.16
|
$376,237
|
+16.07% (+1,207)
|
+0%
|
|
2025 Q2
|
0.00%
|
7,510
|
$38.40
|
$288,384
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.